Allarity Therapeutics, Inc. (ALLR): debt financing — Allarity enters $350K secured note with 3i LP; amends preferred conversion price to $8.00

Allarity Therapeutics, Inc.

Issued $350,000 secured promissory note to 3i LP, maturing July 31, 2023, at 5% annual interest.
Note secured by all company assets; proceeds for working capital and general corporate purposes.
Filed Second Certificate of Amendment reducing Series A Preferred conversion price from $0.75 to $8.00, reflecting 1:40 reverse stock split.
Outstanding obligations payable at next financing or convertible into 486 Series A Preferred shares if insufficient proceeds.
3i LP is the sole holder of Series A Preferred and has existing relationship with the company.

item 1.01 item 2.03 item 3.02 item 5.03 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Debt Financings SEC 8-K Item 2.03/2.04 confidence 0.9

Allarity Therapeutics, Inc. incurred loan of $350,000 with 3i LP at 5% per annum maturing July 31, 2023.

Instrument: loan
Principal: $350,000
Counterparty: 3i LP
Rate: 5% per annum
Maturity: July 31, 2023
Event: incurrence

Exact text from the filing

Under the Purchase Agreement, the Company has authorized the sale and issuance of a secured promissory note in an aggregate principal amount of $350,000 to be issued at closing (the “Note”). The closing for the Note occurred on June 30, 2023 and the purchase price for the Note was paid in cash (“Closing”). The Note matures on July 31, 2023, carries an interest rate of at 5% per annum

View on SEC.gov

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.85

Allarity Therapeutics, Inc. entered into Secured Note Purchase Agreement with 3i LP valued at $350,000 (effective 2023-06-29).

Action: entry
Agreement: notes offering
Counterparty: 3i LP
Value: $350,000
Effective: 2023-06-29

Exact text from the filing

On June 29, 2023, Allarity Therapeutics, Inc. (the “Company”) entered into a Secured Note Purchase Agreement (“Purchase Agreement”) with 3i LP, the sole holder of the Company’s outstanding shares of Series A Preferred Stock. Under the Purchase Agreement, the Company has authorized the sale and issuance of a secured promissory note in an aggregate principal amount of $350,000

View on SEC.gov

101 debt financings filed in the last 30 days. Browse all debt financings →

Allarity Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001213900-23-053500

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.